Abstract
Recently, during the development of COVID-19 pandemic, several publications have warned of possible cutaneous manifestations in association with this novel coronavirus (SARS-CoV-2). In our hospital we have created a multidisciplinary unit with a specific protocol to attend patients with these manifestations. Inclusion criteria consisted of patients who, during the development of the pandemic, were clinically suspected and/or microbiologically confirmed of COVID-19 and had a recent-onset skin rash (within the last 4 weeks). All patients underwent biochemistry, hematimetry and serology for parvovirus B19 and for human herpesvirus 6 (HHV-6), as well as other serologies and a coagulation study according to clinical manifestations. Based on the findings, we also randomly selected 12 hospitalized patients, with similar median age, with COVID-19 but without cutaneous manifestations, and we requested HHV-6 serology. The SARS-CoV-2 antibody assay was Roche´s Elecsys® Anti-SARS-CoV-2 and the HHV-6 antibody assay was ELISA-VIDITEST anti-HHV-6 IgM (Vidia®). The protocol was approved by the Aragon Ethical Committee for Clinical Research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
